81 results about "Pre diabetes" patented technology

The invention relates to the use of compounds to treat a number of conditions, such as a pre-diabetes condition, type 1 diabetes, type 2 diabetes, hyperglycemia, insulin resistance and glucose intolerance. Compounds that can be used in one or more of the treatment methods include 3β,7β,16α,17β-tetrahydroxyandrost-5-ene, 3α,7β,16α,17β-tetrahydroxyandrost-5-ene, 3β,7β,16α,17β-tetrahydroxyandrost-5-ene, 3β,16α,17β-trihydroxyandrost-5-ene-7-one, 3β,7β,17β-trihydroxy-17α-ethynylandrost-5-ene, 3β,17β-dihydroxy-17α-ethynylandrost-5-ene-7-one and 3β,7α,17β-trihydroxy-17α-ethynylandrost-5-ene.

Pharmaceutical compositions include compounds with cytokinin activity to modulate glucose and/or lipid metabolism in a mammal. Especially preferred compounds include those comprising a purine scaffold, and it is further preferred that contemplated compositions are employed to prevent and/or treat various diseases, including pre-diabetes, insulin resistance, type-2 diabetes, Syndrome X, and dyslipidemia In still further preferred aspects, compounds with cytokinin activity are used to activate AMPK and/or Akt. Consequently, various diseases associated with dysregulation of AMPK and/or Akt may be treated using the compounds of the present inventive subject matter.

The present invention relates to a method for treating disease or condition susceptible to amelioration by AMPK activators and compounds of formula which are useful to activate AMP-activated protein kinase (AMPK) and the use of the compounds in the prevention or treatment of disease, including pre-diabetes, type 2 diabetes, syndrome X, metabolic syndrome and obesity.

The present invention relates to one or more SGLT2 inhibitors or pharmaceutically acceptable forms thereof for use in the treatment and/or prevention of a metabolic disorder in a feline animal, preferably wherein the metabolic disorder is one or more selected from the group consisting of: ketoacidosis, pre-diabetes, diabetes mellitus type 1 or type 2, insulin resistance, obesity, hyperglycemia, impaired glucose tolerance, hyperinsulinemia, dyslipidemia, dysadipokinemia, subclinical inflammation, systemic inflammation, low grade systemic inflammation, hepatic lipidosis, atherosclerosis, inflammation of the pancreas, neuropathy and/or Syndrome X (metabolic syndrome) and/or loss of pancreatic beta cell function and/or wherein the remission of the metabolic disorder, preferably diabetic remission, is achieved and/or maintained.

An electronic system is provided that simulates a glucose-insulin metabolic system of a T2DM or prediabetic subject, wherein the system includes a subsystem that models dynamic glucose concentration in a T2DM or prediabetic subject, including an electronic module that models endogenous glucose production (EGP(t)), or meal glucose rate of appearance (Ra(t>>, or glucose utilization (U(t)), or renal excretion of glucose (B(t)), a subsystem that models dynamic insulin concentration in said T2DM or prediabetic subject, including an electronic module that models insulin secretion (S(t)), an electronic database containing a population of virtual T2DM or prediabetic subjects, each virtual subject having a plurality of metabolic parameters, and a processing module that calculates an effect of variation of at least one metabolic parameter value on the glucose insulin metabolic system of a virtual subject by inputting the plurality of metabolic parameter values.

The invention relates to analogs of 4-hydroxyisoleucine, and to lactones, pharmaceutically acceptable salts, and prodrugs thereof, to processes for their preparation, and to pharmaceutical compositions comprising the same. The analogs of the invention stimulate both glucose uptake and insulin secretion, and may thus be useful for the prevention and treatment of disorders of carbohydrate or lipid metabolism, including diabetes mellitus (type 1 and type 2 diabetes), pre-diabetes, and Metabolic Syndrome.

The invention provides various novel compositions of berberine in combination with pharmacologically active organic acids, and related methods of their use in treating various diseases or disorders. The invention further provides various novel compounds prepared from berberine and pharmacologically active organic acids and prepared from ursodeoxycholic acid and pharmacologically active organic bases, and pharmaceutical compositions thereof, and methods of their preparation and therapeutic use in treating and/or preventing various diseases or disorders. The compounds and pharmaceutical compositions of the invention can be utilized to treat various diseases or disorders, such as diabetes, diabetic complications, dyslipidemia, hyperlipidemia, obesity, metabolic syndromes, pre-diabetes, atherosclerosis, heart diseases, neurodegenerative diseases, sarcopenia, muscle atrophy, inflammation, cancer and liver diseases and conditions such as fatty liver, non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, cholestatic liver diseases or graft-versus-host disease of the liver. The compounds of this invention are also useful in improving liver functions in chronic viral associated liver diseases and alcohol-related liver diseases.

The invention relates to a pre-diabetes PC-WeChat intelligent management and follow-up system. The system is composed of a hardware system, a software system and a functional layer, wherein the hardware system is composed of a patient end, a doctor end and a server end, the patient end is provided with an intelligent patient management engine, an intelligent patient abnormality analysis engine andan intelligent question answering robot, the doctor end is provided with a scientific research management system, a follow-up management system and a patient management system, the server end is composed of an EDC application server, an EDC follow-up server, an EDC data server and a WeChat server, the EDC application server is provided with an electronic medical record system, and the EDC data server is provided with a knowledge database management platform and a specialized disease knowledge database. The system is advantaged in that automatic information collection for pre-diabetes patientmanagement is achieved, real-time query and intelligent push of the prevention and control knowledge are achieved, doctors are assisted in management, research and clinical research, efficiency of managing patients is improved, and communication between the doctors and the patients is facilitated.

The present invention relates to one or more SGLT2 inhibitors or pharmaceutically acceptable forms thereof for use in the treatment and/or prevention of a metabolic disorder in a canine animal, preferably wherein the metabolic disorder is one or more selected from the group consisting of: ketoacidosis, pre-diabetes, insulin dependent diabetes mellitus, insulin resistance diabetes, insulin resistance, obesity, hyperglycemia, hyperglycemia induced cataract formation, impaired glucose tolerance, hyperinsulinemia, dyslipidemia, dysadipokinemia, subclinical inflammation, systemic inflammation, low grade systemic inflammation, hepatic lipidosis, inflammation of the pancreas, metabolic disorder consequences, such as hypertension, renal dysfunction and/or muscoskeletal disorders, and/or Syndrome X (metabolic syndrome), wherein preferably the development of hyperglycemia induced cataract formation is prevented or remission is achieved and/or wherein preferably the development of metabolic disorder consequences, such as hypertension, renal dysfunction and/or muscoskeletal disorders, is prevented or progression is slowed or remission is achieved.

The invention discloses a recombinant adiponectin antigen. A preparation method of the recombinant adiponectin antigen includes the steps of a, culturing a high-expression recombinant human full-length adiponectin protein cell strain in a high-glucose DMEM culture medium under oxygen input quantity of 0.25-0.75L/minute, carbon dioxide quantity of 5-10%, bovine serum quantity of 5-10% and rotationspeed of 100-200rpm to allow the cell number of the cell strain to reach 1-3*10<7>; b, replacing the culture medium with a serum-free culture medium, adding 0.5% of vitamin C, and allowing the cell strain to keep the cell number of 1-3*10<7> and continuously express adiponectin for 4-10 days. The invention further discloses an adiponectin antibody, adiponectin antibody nano latex particles and a kit containing the antigen and the antibody nano latex particles. The kit using the nano latex-enhanced turbidimetric immunoassay to detect adiponectin is high in accuracy, real and reliable in data and good in predicting effect on type 2 diabetes and pre-diabetes.

The invention relates to an AMPK activating compound and its use in the preparation of drugs for preventing or treating diseases or physiological states which can be improved by an AMPK activator and comprise pre-diabetes, insulin resistance, type II diabetes, X-syndromes, metabolism syndromes and obesity. The compound reduces the blood plasma glucose amount by above 30wt%, reduces the triglyceride amount by above 35wt% and reduces the body weight by above 15%.

Biomarkers for pre-Diabetes, Diabetes and/or a Diabetes related conditions, and methods of their use, including the biomarkers in Tables 1 and 2 such as peroxiredoxin-2, complement C1q subcomponent subunit B, sulfhydryl oxidase 1 and apolipoprotein A-IV.

A method for treating a patient suffering diabetes or pre-diabetes is disclosed. In brief, this treatment involves delivering a micro-current to the patient, in accordance with a defined therapeutic regime. More specifically, this invention relates to the treatment of diabetes, by means of electrostimulation, so as to correct/abate the biological processes which are believed to be destructive of the cells involved in the production of insulin. In practice a body conformable, electrode wrap is secured to an individual, and an alternating, direct current applied to the electrode wrap, within the range of from 20 milli-amperes to 1 atto-ampere (1×10⁻¹⁸ amps). The micro current is preferably an alternating direct current having a frequency in the range of from 0.00065 Hz to 0.00085 Hz. This therapeutic regime is effective in the stabilization of blood sugar levels in insulin dependent diabetics.

The invention discloses an edible blend oil for prevention and treatment of pre-diabetes, and belongs to the field of blend oil manufacturing technology. The edible blend oil for prevention and treatment of pre-diabetes includes the following ingredients: soybean oil, olive oil, seal oil, omega-3 fatty acid, omega-6 fatty acid, essential amino acid, fat-soluble vitamin, water-soluble vitamin, trace element, fructose, glucose, carotene, chlorophyll, etc. The edible blend oil for prevention and treatment of pre-diabetes provided by the invention can replace traditional peanut oil for eating. Theedible blend oil for prevention and treatment of pre-diabetes contains a variety of beneficial ingredients, has more balanced nutrition, and contains a large number of linoleic acid, linolenic acid and unsaturated acid, alpha-linolenic acid, olive polyphenols, etc. The edible blend oil for prevention and treatment of pre-diabetes is low in cholesterol content and good for patients with hyperlipemia, hypertension, hyperglycemia, obesity and cardiovascular and cerebrovascular diseases after long-term consumption. The edible blend oil for prevention and treatment of pre-diabetes has good antioxidant and free radical scavenging abilities, and the edible blend oil is beneficial to the prevention of diabetic cardiovascular diseases and good in blood sugar lowering effect.

The present disclosure relates to pharmaceutical compositions of solid dosage form for intraoral administration that provides effective delivery of insulin and insulin analogs via the transmucosal route. Also provided are methods for treating pre-diabetes, diabetes and metabolic syndrome in a subject in need thereof.

The present invention provides compounds that are surrogates of post-translationally modified proteins and uses thereof. Numerous diseases are associated with post-translationally modified proteins that are difficult to obtain in homogenous form and in quantities needed for immunization and use as convenient standards, calibrators, and/or reference compounds that facilitate the detection and analysis of endogenous post-translationally modified proteins. The surrogate compounds of the invention typically comprise antigenic epitopes (one of which carries a post-translational modification) that are tethered by a flexible and hydrophilic linker. The resulting compound behaves like a surrogate of the post-translationally modified protein because it preserves the character of the included antigens and allows recognition by specific antibodies targeting the individual antigens. The surrogate compounds may be prepared by covalently joining two or more polypeptide epitopes using one or more linkers, wherein at least one of the epitopes comprises a post-translational modification. In one aspect, the surrogate compounds of the invention comprise a C-terminal epitope and a glycated epitope of human CD59. The inventive methods allow quantification of the levels of glycated CD59 in the serum in human subjects, particularly those with diabetes or pre-diabetes. This technological platform of post-translationally modified protein surrogates can be applied to other diseases associated with post-translationally modified proteins (e.g., autoimmune diseases such as multiple sclerosis, rheumatoid arthritis, and systemic lupus erythematosus). In another aspect, the invention provides antibodies that bind specifically to the compounds of the invention and methods for producing such antibodies.